2023 was a troublesome 12 months for the biopharma sector, with several organizations downsizing and restructuring their workforces to remain afloat. There are signs of recovery, as mergers and acquisitions picked up across the pharmaceutical and existence sciences sector from the latter part of 2023 and have ongoing their upswing https://sites.google.com/view/bio-sites/blog